Erik I. Charych

Wyeth Neuroscience 
Cellular, molecular, developmental
"Erik Charych"
Mean distance: 17.23 (cluster 6)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Diggle CP, Sukoff Rizzo SJ, Popiolek M, et al. (2016) Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. American Journal of Human Genetics. 98: 735-43
Campbell BM, Charych E, Lee AW, et al. (2014) Kynurenines in CNS disease: regulation by inflammatory cytokines. Frontiers in Neuroscience. 8: 12
Charych EI, Brandon NJ. (2014) Molecular And Cellular Understanding of PDE10A: A Dual-Substrate Phosphodiesterase with Therapeutic Potential to Modulate Basal Ganglia Function Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Drug Discovery. 247-268
Sweet ES, Previtera ML, Fernández JR, et al. (2011) PSD-95 alters microtubule dynamics via an association with EB3. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 1038-47
Wang Q, Charych EI, Pulito VL, et al. (2011) The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function. Molecular Psychiatry. 16: 1006-23
Charych EI, Jiang LX, Lo F, et al. (2010) Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 9027-37
Hayashi MA, Guerreiro JR, Charych E, et al. (2010) Assessing the role of endooligopeptidase activity of Ndel1 (nuclear-distribution gene E homolog like-1) in neurite outgrowth. Molecular and Cellular Neurosciences. 44: 353-61
Grauer SM, Pulito VL, Navarra RL, et al. (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. 331: 574-90
Charych EI, Liu F, Moss SJ, et al. (2009) GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology. 57: 481-95
Collins DM, Murdoch H, Dunlop AJ, et al. (2008) Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cellular Signalling. 20: 2356-69
See more...